Bioamber (BIOA) versus AdvanSix (ASIX) Critical Contrast
Bioamber (NYSE: BIOA) and AdvanSix (NYSE:ASIX) are both small-cap basic materials companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations.
Insider and Institutional Ownership
30.0% of Bioamber shares are owned by institutional investors. Comparatively, 71.3% of AdvanSix shares are owned by institutional investors. 8.3% of Bioamber shares are owned by insiders. Comparatively, 2.7% of AdvanSix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Bioamber and AdvanSix’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Bioamber||$8.27 million||2.77||-$22.47 million||($0.70)||-0.63|
|AdvanSix||$1.19 billion||1.10||$34.14 million||$1.59||27.14|
AdvanSix has higher revenue and earnings than Bioamber. Bioamber is trading at a lower price-to-earnings ratio than AdvanSix, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings for Bioamber and AdvanSix, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Bioamber presently has a consensus target price of $6.50, indicating a potential upside of 1,377.27%. AdvanSix has a consensus target price of $46.00, indicating a potential upside of 6.60%. Given Bioamber’s higher possible upside, equities analysts plainly believe Bioamber is more favorable than AdvanSix.
This table compares Bioamber and AdvanSix’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
AdvanSix beats Bioamber on 9 of the 12 factors compared between the two stocks.
BioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.
AdvanSix Inc. is an integrated manufacturer of Nylon 6. The Company also sells a variety of other products, all of which are produced as part of the Nylon 6 resin manufacturing process primarily, including caprolactam, ammonium sulfate fertilizers and other chemical intermediates. The Company operates primarily through its integrated manufacturing sites located in Frankford, Pennsylvania, Hopewell, Virginia, and Chesterfield, Virginia. The Company offers ammonium sulfate, which is used by customers as a nitrogen-based fertilizer. It produces ammonium sulfate fertilizer as part of its manufacturing process. The Company manufactures ammonium sulfate fertilizers including Sulf-N and Sulf-N 26. The Company provides AdvanSix Aegis nylon resins and Aegis barrier nylon resins. Its nylon resins are a preferred choice in food, liquid, and consumer packaging along with mono/multifilament products, carpet fibers, automotive compounding and more. It offers Capran biaxially oriented nylon films.
Receive News & Ratings for Bioamber Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber and related companies with MarketBeat.com's FREE daily email newsletter.